Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Hunter

Obstetrics & Gynecology Charleston, WV Medical Doctor

NPI 1487657631 CMS profile 22335

830 Pennsylvania Ave, Ste 402, Charleston, WV 25302

Open in the dashboard

General payments

$6,398

316 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Hunter of Charleston, WV is reported in the CMS Open Payments database as having received $6,398 across 316 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,091 46
2024 General $945 42
2023 General $945 46
2022 General $1,109 51
2021 General $948 50
2020 General $612 39
2019 General $747 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Hunter
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Paul Hunter were reported at $1,091. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Paul Hunter Obstetrics & Gynecology median Middle half National median
2019 $747 $172 $62–$391 $163
2020 $612 $94 $36–$222 $114
2021 $948 $136 $42–$369 $132
2022 $1,109 $160 $50–$433 $149
2023 $945 $169 $56–$423 $160
2024 $945 $152 $50–$371 $164
2025 $1,091 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $959 30 payments
  2. Pfizer Inc. $761 48 payments
  3. AbbVie, Inc. $608 35 payments
  4. Astellas Pharma US Inc $554 33 payments
  5. Exeltis, USA Inc. $526 30 payments
  6. Sumitomo Pharma America, Inc. $316 17 payments
  7. Hologic, LLC $309 13 payments
  8. Myovant Sciences Inc. $285 16 payments
  9. Sage Therapeutics, Inc. $282 14 payments
  10. Exact Sciences Corporation $242 14 payments
  11. Other $1,554 66 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,314 309 payments
  2. Education $83 7 payments
Products named General payments · program years 2019–2025
  1. PREMARIN $921 57 payments
  2. EVENITY $809 28 payments
  3. Prolia $640 26 payments
  4. ESTRING $497 31 payments
  5. MYFEMBREE Hormone Therapy $425 24 payments
  6. MYFEMBREE Genitourinary (Sexual Health);Womens Health $344 19 payments
  7. MYRBETRIQ $336 22 payments
  8. COLOGUARD $305 21 payments
  9. ORILISSA $301 18 payments
  10. ZURZUVAE $282 14 payments
  11. Other $4,333 224 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

129

Median for Obstetrics & Gynecology: 65

Drug cost

$42,946

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

58.1%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 36 $32,196
Premarin Estrogens, Conjugated Brand 16 $7,067
Estradiol (Twice Weekly) Estradiol Brand 23 $2,336
Ibandronate Sodium Generic 21 $746
Estradiol Generic 19 $507
Norethindrone Acetate Generic 14 $93

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EVENITY
  • Amgen Inc. $214
$214 — —
MYFEMBREE
  • Sumitomo Pharma America, Inc. $125
  • PFIZER INC. $5
$130 — —
SLYND
  • Exeltis, USA Inc. $129
$129 — —
Prolia
  • Amgen Inc. $82
$82 — —
Veozah
  • Astellas Pharma US Inc $60
$60 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

316 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record